Equities Analysts Offer Predictions for Inozyme Pharma, Inc.’s Q1 2025 Earnings (NASDAQ:INZY)

Inozyme Pharma, Inc. (NASDAQ:INZY) – Wedbush issued their Q1 2025 earnings per share (EPS) estimates for Inozyme Pharma in a note issued to investors on Tuesday, May 7th. Wedbush analyst D. Nierengarten forecasts that the company will post earnings per share of ($0.46) for the quarter. Wedbush has a “Outperform” rating and a $15.00 price objective on the stock. The consensus estimate for Inozyme Pharma’s current full-year earnings is ($1.46) per share.

A number of other research firms also recently commented on INZY. Bank of America decreased their target price on Inozyme Pharma from $16.00 to $14.00 and set a “buy” rating on the stock in a research report on Tuesday, April 9th. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 target price on shares of Inozyme Pharma in a research report on Wednesday. Finally, HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of Inozyme Pharma in a research report on Wednesday, March 13th.

Inozyme Pharma Price Performance

NASDAQ:INZY opened at $4.64 on Thursday. The company has a current ratio of 13.36, a quick ratio of 13.36 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $287.03 million, a P/E ratio of -3.34 and a beta of 1.54. Inozyme Pharma has a 12 month low of $2.69 and a 12 month high of $7.80. The business’s 50-day moving average is $5.62 and its 200 day moving average is $4.75.

Inozyme Pharma (NASDAQ:INZY) last posted its quarterly earnings results on Tuesday, March 12th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.04).

Institutional Investors Weigh In On Inozyme Pharma

Large investors have recently added to or reduced their stakes in the stock. Eventide Asset Management LLC bought a new position in shares of Inozyme Pharma during the third quarter valued at approximately $13,125,000. FMR LLC grew its stake in shares of Inozyme Pharma by 229.2% during the third quarter. FMR LLC now owns 2,465,232 shares of the company’s stock valued at $10,354,000 after buying an additional 1,716,398 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its stake in shares of Inozyme Pharma by 30.3% during the third quarter. Adage Capital Partners GP L.L.C. now owns 5,537,500 shares of the company’s stock valued at $23,258,000 after buying an additional 1,287,500 shares during the last quarter. Affinity Asset Advisors LLC grew its stake in shares of Inozyme Pharma by 83.5% during the third quarter. Affinity Asset Advisors LLC now owns 1,379,852 shares of the company’s stock valued at $5,795,000 after buying an additional 628,056 shares during the last quarter. Finally, Laurion Capital Management LP grew its stake in shares of Inozyme Pharma by 170.5% during the third quarter. Laurion Capital Management LP now owns 677,329 shares of the company’s stock valued at $2,845,000 after buying an additional 426,961 shares during the last quarter. 88.30% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Inozyme Pharma news, CEO Douglas A. Treco sold 7,523 shares of the business’s stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold at an average price of $6.94, for a total transaction of $52,209.62. Following the sale, the chief executive officer now directly owns 20,665 shares of the company’s stock, valued at $143,415.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 11.88% of the stock is currently owned by insiders.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.